Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen

I‐Chun Chen(National Taiwan University Hospital), Yen‐Shen Lu(National Taiwan University Hospital)
Scientific Reports
August 23, 2017
10.1038/s41598-017-10555-z
Cited by 33

Related Papers

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
|New England Journal of Medicine|2019|1k
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma
|Hepatology|2007|91